Description:

Gynecologic Oncology Group Biomarker Reporting Form (Form BMR) Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4FF32823-727F-27D4-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4FF32823-727F-27D4-E044-0003BA3F9857

Keywords:
Versions (2) ▾
  1. 9/19/12
  2. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Fallopian Tube Cancer NCT00951496 Lab - Gynecologic Oncology Group Biomarker Reporting Form (Form BMR) - 2760081v1.0

No Instruction available.

  1. StudyEvent: Gynecologic Oncology Group Biomarker Reporting Form (Form BMR)
    1. No Instruction available.
Header Module
Biomarker Information
Were biomarkers assessed during this reporting period
Comments

Similar models